Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin liposomal - Perrigo

Next Previous
X
Search
Drug Profile

Doxorubicin liposomal - Perrigo

Alternative Names: Myocet; NSC 620212; TLC D99; TLC Dox99

Latest Information Update: 04 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elan Corporation
  • Developer Sopherion Therapeutics; Zeneus Pharma
  • Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
  • Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 25 Jan 2024 Teva out-licenses commercial rights of Myocet® to CHEPLAPHARM Group
  • 09 Apr 2021 Discontinued - Phase-III for Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in India, Russia, Argentina, USA (IV), prior to April 2021
  • 28 Sep 2016 Efficacy and adverse events data from a phase II trial in Breast cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top